270 related articles for article (PubMed ID: 18674531)
1. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats.
Capitelli C; Sereniki A; Lima MM; Reksidler AB; Tufik S; Vital MA
Eur J Pharmacol; 2008 Oct; 594(1-3):101-8. PubMed ID: 18674531
[TBL] [Abstract][Full Text] [Related]
2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
3. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice.
Hong Z; Wang G; Gu J; Pan J; Bai L; Zhang S; Chen SD
Eur J Neurosci; 2007 Sep; 26(6):1500-8. PubMed ID: 17714494
[TBL] [Abstract][Full Text] [Related]
4. Fucoidan protects against dopaminergic neuron death in vivo and in vitro.
Luo D; Zhang Q; Wang H; Cui Y; Sun Z; Yang J; Zheng Y; Jia J; Yu F; Wang X; Wang X
Eur J Pharmacol; 2009 Sep; 617(1-3):33-40. PubMed ID: 19545563
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.
Kumar P; Kaundal RK; More S; Sharma SS
Behav Brain Res; 2009 Feb; 197(2):398-403. PubMed ID: 18983875
[TBL] [Abstract][Full Text] [Related]
6. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats.
Reksidler AB; Lima MM; Zanata SM; Machado HB; da Cunha C; Andreatini R; Tufik S; Vital MA
Eur J Pharmacol; 2007 Apr; 560(2-3):163-75. PubMed ID: 17320073
[TBL] [Abstract][Full Text] [Related]
7. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
Reksidler AB; Lima MM; Dombrowski P; Andersen ML; Zanata SM; Andreatini R; Tufik S; Vital MA
J Neurosci Methods; 2008 Jan; 167(2):268-77. PubMed ID: 17931705
[TBL] [Abstract][Full Text] [Related]
8. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations.
Ferro MM; Bellissimo MI; Anselmo-Franci JA; Angellucci ME; Canteras NS; Da Cunha C
J Neurosci Methods; 2005 Oct; 148(1):78-87. PubMed ID: 15939479
[TBL] [Abstract][Full Text] [Related]
9. Does melatonin help save dopaminergic cells in MPTP-treated mice?
Ma J; Shaw VE; Mitrofanis J
Parkinsonism Relat Disord; 2009 May; 15(4):307-14. PubMed ID: 18793863
[TBL] [Abstract][Full Text] [Related]
10. PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease.
Barbiero JK; Santiago R; Tonin FS; Boschen S; da Silva LM; Werner MF; da Cunha C; Lima MM; Vital MA
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Aug; 53():35-44. PubMed ID: 24593945
[TBL] [Abstract][Full Text] [Related]
11. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J
J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine.
Barbiero JK; Santiago RM; Persike DS; da Silva Fernandes MJ; Tonin FS; da Cunha C; Lucio Boschen S; Lima MM; Vital MA
Behav Brain Res; 2014 Nov; 274():390-9. PubMed ID: 25127682
[TBL] [Abstract][Full Text] [Related]
15. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
[TBL] [Abstract][Full Text] [Related]
16. Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.
Monaghan MM; Leddy L; Sung ML; Albinson K; Kubek K; Pangalos MN; Reinhart PH; Zaleska MM; Comery TA
Neurodegener Dis; 2010; 7(1-3):153-9. PubMed ID: 20197696
[TBL] [Abstract][Full Text] [Related]
17. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
Bian GL; Wei LC; Shi M; Wang YQ; Cao R; Chen LW
Brain Res; 2007 May; 1150():55-61. PubMed ID: 17397812
[TBL] [Abstract][Full Text] [Related]
18. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
[TBL] [Abstract][Full Text] [Related]
19. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
20. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease.
Sharma R; McMillan CR; Tenn CC; Niles LP
Brain Res; 2006 Jan; 1068(1):230-6. PubMed ID: 16375867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
